Page 279 - 2021_05-Haematologica-web

Letters to the Editor
sible, resulting in highly concordant MRD data. Moreover, QA programs using fresh material from MM patients are a straightforward and effective way to mon- itor and improve MFC MRD data quality within clinical trials. This is of particular relevance for studies that depend on reference laboratories with no or limited prior experience with the EuroFlow protocols, as these are not always fully adhered to from the beginning. We, there- fore, strongly recommend the incorporation of both the annual EuroFlow QA rounds and trial group-specific QA rounds with fresh MM samples in future clinical trial designs to ensure further advancement of the field in terms of standardized MFC MRD response assessment.
Davine Hofste op Bruinink,1,2* Stefania Oliva,3* Lucie Rihova,4 Alexander Schmitz,5 Milena Gilestro,3 Jeroen te Marvelde,2 Romana Kralova,4 Helle Høholt,5
1 5† 6 Annemiek Broijl, Hans Erik Johnsen, Roman Hajek,
Mario Boccadoro,3 Pieter Sonneveld,1 Paola Omedè3# and Vincent H.J. van der Velden2# on behalf of the European Myeloma Network7
1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 2Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; 3Myeloma Unit, Division of Hematology, University of Turin, Turin, Italy; 4Department of Hematology, University Hospital Brno, Brno, Czech Republic; 5Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark, 6Department of Hemato- oncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic and 7https://www.myeloma-europe.org
*DHoB and SO contributed equally as co-first authors. #PO and VvdV contributed equally as co-senior authors. †Deceased
Correspondence:
DAVINE HOFSTE OP BRUININK - d.hofsteopbruinink@erasmusmc.nl VINCENT H.J. VAN DER VELDEN - v.h.j.vandervelden@erasmusmc.nl doi:10.3324/haematol.2020.267831 Received: August 7, 2020.
Accepted: September 23, 2020.
Pre-published: October 5, 2020.
Disclosures: SO has received honoraria from Celgene, Janssen, Amgen, and Adaptive Biotechnologies. AB has received honoraria or advisory board remuneration from Celgene, Janssen, Amgen, and Takeda. PS has received research support and advisory board remuneration from Janssen, Celgene, and Amgen. DHoB, LR, AS, MG, JtM, RK, HH, HEJ, RH, MB, PO, and VvdV have no poten- tial conflicts of interest.
Contributions: DHoB and VvdV conceived the study. DHoB, SO, LR, AS, MG, JtM, RK, HH, PO, and VvdV performed the investiga- tions. DHoB, SO, and AB were responsible for resources. DHoB, SO, LR, AS, PO, and VvdV managed the data. DHoB wrote the original draft of the work, SO, LR, AS, MG, JtM, RK, HH, AB, RH, MB, PS, PO, and VvdV reviewed and edited it. DHoB: preparation of
figures. HEJ, RH, MB, PS, PO, and VvdV supervised the study. DHoB was the project administrator. RH and PS acquired funding.
Acknowledgments: the authors would like to thank all patients for providing material for this study and members from the clinical teams and laboratories at Aalborg University Hospital, Denmark, University Hospital Brno, Czech Republic, Erasmus MC Rotterdam, the Netherlands and University of Torino, Italy for their assistance.
Funding: this work was supported by grants from the European Myeloma Network and the Ministry of Health of the Czech Republic (grant number 17-30089A).
References
1. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommen- dations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-4695.
2. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28-35.
3. Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual dis- ease testing in multiple myeloma by flow cytometry: major hetero- geneity. Blood. 2013;122(6):1088-1089.
4. van Dongen JJ, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-1975.
5. Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow stan- dardization of flow cytometer instrument settings and immunophe- notyping protocols. Leukemia. 2012;26(9):1986-2010.
6. Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094- 2103.
7.Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal resid- ual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346.
8. Scott SD, Fletcher M, Whitehouse H, et al. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use? Cytometry B Clin Cytom. 2019;96(3):201-208.
9. Kalina T, Brdickova N, Glier H, et al. Frequent issues and lessons learned from EuroFlow QA. J Immunol Methods. 2019;475:112520.
10. Oliva S, Hofste op Bruinink D, RÍhová L, et al. Minimal residual dis- ease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: results from the EMN02/HO95 phase 3 trial. J Clin Oncol.
2017;35(15_suppl):8011.
11. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-
cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multi- ple myeloma (EMN02/HO95): a multicentre, randomised, open- label, phase 3 study. Lancet Haematol. 2020;7(6):e456-e468.
12. Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784-792.
13. Sanoja-Flores L, Flores-Montero J, Garces JJ, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8(12):117.
14. Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-438.
15. Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31-39.
haematologica | 2021; 106(5)
1499